Medical marijuana has picked up considerable momentum after a U.S. FDA advisory panel unanimously recommended approval of GW Pharmaceuticals' epilepsy medication, Epidolex.
Anandia plans to accelerate their current breeding efforts to create the next-generation of cannabis plants and, expand their testing capabilities.
Reviews of scientific evidence show promising findings for some, but not all, conditions for which cannabis is considered a treatment – and this evidence is difficult to untangle.
Can Lebanon-grown cannabis provide an alternative treatment for certain chronic ailments? Researchers want to find out.
MMJ is seeking to scientifically assess and prove the effectiveness of their THC/CBD compounds treating and preventing symptoms associated with multiple sclerosis.
Canopy Growth and MSC will work together to pioneer new and standardized testing methods to analyse potency, terpene profiling, pesticides, heavy metals, and mycotoxins as required by Health Canada regulatory standards.
Quadron Cannatech has announced that it has completed the sale of its first mobile extraction module to TLC Botanicals, located in Langley, British Columbia.
A new partnership has plans to improve cannabis plant yield, add diversity, promote immunity, and modify the physical and chemical traits of cannabinoid expressing plants.
Novel cannabinoid formulation, RAPID, is being tested for the treatment of stress and anxiety relief, cognitive focus, various kinds of pain and, migraines and could help curb opioid use.